For more than two years it had the entirety of the market for weight-loss drugs to itself. By 2023 sales of Wegovy had ...

A notable finding is that audiences are split on whether they see more pharma ads in 2025 compared to 2024. Nearly half of ...

Even so, in an interview with The Economist, Mr Doustdar sounded confident that Novo can recover. His prescription is to push ...

The survey showed that while most of the doctors didn’t have top-of-mind awareness of oral semaglutide’s upcoming FDA ...

A federal judicial panel said Monday it would centralize a growing number of lawsuits against Novo Nordisk and Eli Lilly ...

Novo Nordisk finds itself navigating significant operational and market headwinds. The company is intensely focused on maintaining its leadership in the obes ...

Novo Nordisk NVO announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) ...

In the midst of regulatory and political upheaval, biopharma’s R&D engine kept running, churning out highs and lows in equal ...

As Eli Lilly and Novo Nordisk scramble to bring an oral glucagon-like peptide 1 (GLP-1) receptor agonist to market for obesity, much smaller potential rival Structure Therapeutics spotlighted positive ...

Novo Nordisk has the potential to maintain more consistent revenue growth throughout next year. There is an indication that ...

Zealand Pharma may be gearing up for a high-stakes year of obesity readouts, but the Danish biopharma thinks the brain could hold the key to the company’s long-term success. | Zealand Pharma may be ...

Dec 12 (Reuters) - The European Medicines ‌Agency's ​committee on Friday ‌recommended extending the use of Eli Lilly's ...